MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
  •  
  • December 2017

AIVITA Biomedical Announces First Patient Enrolled in Phase II Clinical Trial for Late-Stage Ovarian Cancer

AIVITA Biomedical Executes Deal with Lacore Labs for Asian Distribution of a New Skincare Line

AIVITA Biomedical is a biotechnology company developing personalized vaccines that target COVID-19 and the seed of all cancers using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

Recent News

  • AIVITA Biomedical Announces Case Report Suggesting Positive Collateral Benefits in Systemic Lupus Erythematosus Achieved Through the Use of Its Dendritic Cell Vaccine Kit
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at Advanced Therapies Europe
  • AIVITA Biomedical CEO Dr. Hans Keirstead Awarded OC50 Honor by The Orange County Business Journal
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Present at World Vaccine Congress
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Present at World Vaccine Congress

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2023 | AIVITA Biomedical, Inc.